May 2006
Volume 47, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2006
Results of a Phase I, Dose–Escalation, Safety, Tolerability, and Bioactivity Study of Intravitreous VEGF Trap in Patients With Neovascular Age–Related Macular Degeneration
Author Affiliations & Notes
  • Q.D. Nguyen
    Retina Service, Johns Hopkins Wilmer Eye Inst, Baltimore, MD
  • S.M. Shah
    Retina Service, Johns Hopkins Wilmer Eye Inst, Baltimore, MD
  • D. Browning
    Charlotte Eye, Ear, Nose, and Throat Center, Charlotte, NC
  • P. Sonkin
    Retina–Vitreous Associates, PC, Nashville, TN
  • H. Hudson
    Retina Center, PC, Tucson, AZ
  • K. Chu
    Regeneron Pharmaceuticals, Inc., Tarrytown, NY
  • K. Rich
    Regeneron Pharmaceuticals, Inc., Tarrytown, NY
  • A. Lucas
    Regeneron Pharmaceuticals, Inc., Tarrytown, NY
  • J. Cedarbaum
    Regeneron Pharmaceuticals, Inc., Tarrytown, NY
  • P.A. Campochiaro
    Retina Service, Johns Hopkins Wilmer Eye Inst, Baltimore, MD
  • Footnotes
    Commercial Relationships  Q.D. Nguyen, Regeneron Pharmaceuticals, Inc., F; S.M. Shah, None; D. Browning, Regeneron Pharmaceuticals, Inc., F; P. Sonkin, Regeneron Pharmaceuticals, Inc., F; H. Hudson, Regeneron Pharmaceuticals, Inc., F; K. Chu, Regeneron Pharmaceuticals, Inc., E; K. Rich, Regeneron Pharmaceuticals, Inc., E; A. Lucas, Regeneron Pharmaceuticals, Inc., E; J. Cedarbaum, Regeneron Pharmaceuticals, Inc., E; P.A. Campochiaro, Regeneron Pharmaceuticals, Inc., F; Regeneron Pharmaceuticals, Inc., C.
  • Footnotes
    Support  Regeneron Research Support
Investigative Ophthalmology & Visual Science May 2006, Vol.47, 2144. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Q.D. Nguyen, S.M. Shah, D. Browning, P. Sonkin, H. Hudson, K. Chu, K. Rich, A. Lucas, J. Cedarbaum, P.A. Campochiaro; Results of a Phase I, Dose–Escalation, Safety, Tolerability, and Bioactivity Study of Intravitreous VEGF Trap in Patients With Neovascular Age–Related Macular Degeneration . Invest. Ophthalmol. Vis. Sci. 2006;47(13):2144.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To determine the safety, tolerability, maximum tolerated dose, and bioactivity of intravitreous injection of VEGF Trap in patients with neovascular age–related macular degeneration (AMD).

Methods: : Patients with neovascular AMD who had lesions < 12 disc areas in size with at least 50% active choroidal neovascularization and best–corrected visual acuity (VA) of ≤ 20/40 (ETDRS protocol) received a single intravitreous injection of VEGF Trap at day 0. Safety assessments included eye examinations, vital signs, and laboratory tests (hematology, chemistry, urinalysis, levels of VEGF Trap and antibodies directed against VEGF Trap). Measures of bioactivity were changes from baseline in VA, excess foveal thickness and excess macular volume determined by optical coherence tomography, and lesion size and leakage determined by fluorescein angiography. Patients were monitored for 12 weeks following VEGF Trap administration.

Results: : Three patients at each of 4 dose levels, 0.05, 0.15, 0.5, and 1 mg, have been enrolled. There have been no serious adverse events and no identifiable intraocular inflammation. Excess foveal thickness and excess macular volume decreased rapidly after injection of VEGF Trap. At day 29, excess foveal thickness was reduced by at least 70% in 75% of patients and VA was stable or improved in 75% of patients.

Conclusions: : Intravitreous injection of up to 1 mg of VEGF Trap has been well–tolerated. Although the number of patients in each cohort is small, preliminary evidence of bioactivity in patients with neovascular AMD has been seen. Higher doses are being investigated to identify the ideal dose of VEGF Trap for a phase II trial in patients with neovascular AMD.

Keywords: macula/fovea • choroid: neovascularization • clinical (human) or epidemiologic studies: treatment/prevention assessment/controlled clinical trials 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×